Welcome to our dedicated page for Masimo Corporation news (Ticker: MASI), a resource for investors and traders seeking the latest updates and insights on Masimo Corporation stock.
Masimo Corporation (NASDAQ: MASI) is a leading global medical technology company specializing in the development and manufacturing of innovative noninvasive patient monitoring technologies. For over 27 years, Masimo has been at the forefront of medical advancements, offering a wide array of sensors and devices that enhance patient care and safety. Their products are designed to provide healthcare professionals with critical information to improve clinical decision-making.
Masimo's core business is divided into two segments: healthcare and non-healthcare. The healthcare segment is the primary revenue generator, focusing on noninvasive patient monitoring technologies, hospital automation, connectivity solutions, and remote monitoring devices. Their clinically proven products are widely used in hospitals, emergency rooms, and clinical settings around the world.
The non-healthcare segment encompasses the consumer audio business, which includes the development, manufacturing, marketing, and licensing of premium and luxury audio sound products. This segment is known for its advanced audio integration technologies that appeal to audiophiles and general consumers alike.
Masimo's recent achievements include expanding their product portfolio with advanced remote monitoring solutions, partnering with leading healthcare organizations, and pioneering innovative technologies that address unsolvable medical challenges. Financially, the company is robust, showing consistent growth and a strong market presence.
Masimo’s dedication to improving lives is evident in their mission to save, extend, and enhance the quality of life across all demographics. Their innovative spirit attracts individuals who are passionate about making a significant impact in the medical field. As they continue to innovate, Masimo remains committed to providing top-tier products that meet the evolving needs of the healthcare industry.
Masimo (NASDAQ: MASI) announced findings from a study published in the Journal of Pain & Relief, showing that its product Masimo Bridge® significantly reduces postoperative opioid requirements and pain in kidney donor surgery patients. Conducted by researchers at the University of Pittsburgh, the study found a 75.4% reduction in opioid use and 58.3% reduction in pain levels at 24 hours post-surgery for patients using Bridge. The researchers highlighted the potential of this non-invasive device to help combat opioid dependence amid an ongoing opioid crisis.
Masimo reported its Q2 2021 financial results, with product revenue rising 1.4% to $305.1 million. However, the constant currency basis showed a slight decline of 0.1%. The GAAP operating margin improved to 21.3%, while non-GAAP operating margin increased to 23.4%. Net income stood at $50.2 million or $0.88 per diluted share, compared to $55.8 million or $0.96 in Q2 2020. For 2021, the company updated its full-year revenue guidance to $1.216 billion, reflecting a 6.3% growth.
Masimo (NASDAQ: MASI) is set to release its second quarter 2021 financial results on July 27, 2021, after market close. The results will be discussed in a conference call at 1:30 p.m. PT, led by CEO Joe Kiani and CFO Micah Young. Participants can register for the call via a provided link to receive dial-in details. Masimo specializes in medical technology, focusing on innovative monitoring solutions that improve patient outcomes. Its Masimo SET® technology has been validated in over 100 studies, showcasing its effectiveness in clinical settings.
Masimo (NASDAQ: MASI) has released findings from a study in the Journal of Critical Care showing that two parameters from Masimo SedLine®—Patient State Index (PSi) and Suppression Ratio (SR)—can accurately predict neurological outcomes and long-term survival in post-cardiac arrest ICU patients. The study indicates that low values of PSi and SR correlate with higher mortality rates at 180 days, establishing their effectiveness as prognostic tools. This may influence treatment plans and care decisions in critical care settings.
Masimo (NASDAQ: MASI) has received FDA 510(k) clearance for its Radius Tº™, a wearable thermometer for continuous, noninvasive body temperature monitoring. Suitable for patients aged five and older, it features Bluetooth connectivity for easy integration with Masimo's monitoring solutions and smartphone applications. The device supports hospital automation and streamlines workflows with its single-patient use design. Radius Tº offers enhanced accuracy compared to traditional thermometers, providing critical temperature data for both clinicians and consumers. This clearance marks a significant expansion in Masimo's temperature monitoring capabilities.
Masimo (NASDAQ: MASI) announced a study in the Turkish Journal of Medical Sciences demonstrating that the Oxygen Reserve Index (ORi) can guide oxygenation during one-lung ventilation (OLV) in thoracic surgery. Conducted on 103 patients, the study concluded that ORi-guided oxygen titration might reduce hospital stays and enhance patient safety by minimizing hyperoxic conditions. Findings indicated a significantly shorter duration of OLV and lower FiO2 values in ORi-monitored groups. ORi, however, is not yet FDA-cleared for use in the U.S.
Masimo (NASDAQ: MASI) announced its management will participate in the UBS Global Healthcare Virtual Conference on May 26, 2021, at 2:00 p.m. Eastern Time. A live webcast will be accessible on the Masimo website, with a replay available afterward.
Masimo is a global medical technology company specializing in advanced monitoring systems and solutions aimed at improving patient outcomes and reducing healthcare costs. Its innovative technologies, including Masimo SET®, are widely used in hospitals globally, showcasing significant advantages over traditional methods.
Masimo (NASDAQ: MASI) has released a study demonstrating the benefits of its Patient SafetyNet™ system. Conducted by researchers at Nippon Medical School, the study revealed that the implementation of this technology led to a 61.3% reduction in nursing workload for postoperative respiratory assessments. Nurses reported increased satisfaction with remote monitoring, rising from 78.7% to 89.3% pre- to post-implementation. The findings suggest that continuous monitoring of respiratory rates and oxygen saturation enhances patient safety after general anesthesia.
Spacelabs Healthcare, a division of OSI Systems, has announced an extension of its partnership with Masimo to integrate advanced patient monitoring technologies into Spacelabs multi-parameter monitors. The collaboration will include SET pulse oximetry, NomoLine capnography, and other innovative monitoring solutions.
Both companies aim to enhance patient care by providing deeper insights into patients' physiological conditions, thereby improving outcomes for healthcare providers and patients alike.
Masimo (NASDAQ: MASI) announced a study published in the Journal of Anesthesia & Clinical Research demonstrating the effectiveness of its O3® Regional Oximetry in monitoring septic shock patients. The research, conducted by Medical College Kolkata, found significant correlations between O3 trends and hemodynamic variables, highlighting its potential as a noninvasive predictor of mortality. The study monitored 40 patients, revealing significant differences in cerebral rSO2 between survivors and non-survivors over 72 hours. This suggests O3 may provide valuable insights for managing critically ill patients.
FAQ
What is the current stock price of Masimo Corporation (MASI)?
What is the market cap of Masimo Corporation (MASI)?
What is Masimo Corporation's main business?
How long has Masimo Corporation been in operation?
What are the key segments of Masimo's business?
What products does Masimo offer?
What makes Masimo's products unique?
Who uses Masimo's healthcare products?
What recent achievements has Masimo Corporation accomplished?
What is the financial status of Masimo Corporation?
What is Masimo's mission?